Last updated: September 2, 2026
Opicapone, marketed as Ongentys, is a once-daily catechol-O-methyltransferase inhibitor used with levodopa/carbidopa for Parkinson's disease patients experiencing "off" episodes. The product has established regulatory status in the United States and Europe, but its commercial scale remains modest relative to leading Parkinson's therapies. Neurocrine Biosciences controls U.S. commercialization under a license from Bial, while Bial retains major rights outside the United States.
Ongentys' growth case depends on three factors: conversion of patients from older COMT inhibitors, broader use of once-daily adjunctive therapy, and the timing of generic entry after U.S. regulatory and patent barriers weaken. Its revenue trajectory has been positive, but the product is not a major contributor to Neurocrine's overall financial performance, which is dominated by Ingrezza.
What is opicapone and how does Ongentys work?
Opicapone is a peripheral COMT inhibitor administered once daily with levodopa/carbidopa. It reduces peripheral levodopa metabolism and increases levodopa exposure, which can extend "on" time in patients with Parkinson's disease motor fluctuations.
The principal branded product is Ongentys 50 mg capsules. The FDA approved Ongentys on June 26, 2020, as an adjunctive treatment to levodopa/carbidopa in adults experiencing "off" episodes. The European Commission approved Ongentys in 2016 for the same broad treatment setting. [1][2]
| Attribute |
Opicapone |
| Brand |
Ongentys |
| Active ingredient |
Opicapone |
| Drug class |
Peripheral COMT inhibitor |
| U.S. indication |
Adjunct to levodopa/carbidopa for Parkinson's disease "off" episodes |
| U.S. dosage |
50 mg once daily |
| U.S. sponsor |
Neurocrine Biosciences |
| Original developer |
Bial |
| U.S. approval |
June 26, 2020 |
| European approval |
2016 |
| Primary alternatives |
Entacapone, tolcapone, levodopa formulations, dopamine agonists, MAO-B inhibitors |
Opicapone competes mainly on dosing convenience. Entacapone generally requires administration with each levodopa dose, while opicapone is taken once daily. Tolcapone has greater liver-monitoring burdens and is used less frequently.
Who owns and commercializes opicapone?
Bial developed opicapone and partnered with Neurocrine for the U.S. market. Neurocrine obtained exclusive U.S. rights in 2017. The transaction included an upfront payment, development and regulatory milestones, and royalties or other payments tied to commercialization. Bial commercializes Ongentys in multiple markets outside the United States. [3][4]
| Territory |
Commercial responsibility |
| United States |
Neurocrine Biosciences |
| European markets |
Primarily Bial and local commercialization partners |
| Other international markets |
Bial and regional partners, subject to local agreements |
The arrangement gives Neurocrine access to an approved Parkinson's product without bearing the full cost of original discovery. It also limits the company's global economics because U.S. sales are only one component of the product's worldwide revenue base.
What is the financial trajectory for Ongentys?
Ongentys has produced steady but comparatively small revenue for Neurocrine. Neurocrine reports Ongentys separately from Ingrezza in its annual filings, allowing an assessment of U.S. product momentum.
The company has described growth in Ongentys prescriptions and net product sales since launch. The product benefited from its once-daily dosing, increased field-force activity, and continued diagnosis and treatment of Parkinson's disease patients with motor fluctuations. Its revenue remains immaterial compared with Ingrezza, which generates the overwhelming majority of Neurocrine's commercial sales. [4][5]
| Financial driver |
Effect on Ongentys |
| New patient starts |
Positive |
| Conversion from entacapone |
Positive, particularly where adherence is a concern |
| Generic entacapone pricing |
Negative pressure on branded price |
| Once-daily dosing |
Supports physician and patient adoption |
| Neurology sales infrastructure |
Lowers incremental commercialization cost |
| Limited indication breadth |
Caps market expansion |
| Generic launch risk |
Could compress price and volume after exclusivity loss |
| Bial royalties and license economics |
Reduce Neurocrine's retained margin relative to a wholly owned product |
Ongentys is strategically useful because it expands Neurocrine's presence in movement disorders, but it does not materially diversify the company's financial exposure away from Ingrezza. A substantial decline in Ongentys revenue would have a limited effect on total Neurocrine revenue unless the product becomes a much larger share of the portfolio.
How large is the opicapone market?
The addressable market is the subset of Parkinson's disease patients treated with levodopa/carbidopa who develop predictable motor fluctuations. Parkinson's disease prevalence creates a large underlying patient pool, but only a fraction is eligible for or willing to use a COMT inhibitor.
The commercial opportunity is constrained by several factors:
- Opicapone is an adjunctive therapy rather than a foundational Parkinson's treatment.
- Treatment is generally initiated after patients develop wearing-off or "off" episodes.
- Physicians can choose low-cost generic entacapone or other adjunctive therapies.
- Advanced therapies, including deep brain stimulation and infusion-based treatments, compete for patients with more severe motor complications.
- The product has one principal approved dose and a narrow therapeutic role.
Opicapone's strongest commercial segment is likely patients who need extended levodopa coverage but are poorly suited to multiple daily entacapone dosing. Its value proposition is weaker when payers impose high copayments or when physicians prioritize generic cost savings.
How does opicapone compare with entacapone and tolcapone?
Opicapone has a dosing and safety-positioning advantage over older COMT inhibitors, but it has less price protection because its clinical role overlaps with established generic products.
| Product |
Dosing pattern |
Key commercial advantage |
Key limitation |
| Opicapone |
Once daily |
Convenience and sustained COMT inhibition |
Branded price and patent exposure |
| Entacapone |
With each levodopa dose |
Low-cost generic availability |
High pill burden |
| Tolcapone |
Multiple daily doses |
Potent COMT inhibition |
Liver toxicity monitoring and restricted use |
| Levodopa extended-release products |
Product-specific |
Direct control of levodopa delivery |
Different formulation and titration considerations |
| MAO-B inhibitors |
Usually once daily |
Alternative mechanism |
Different efficacy and interaction profiles |
Opicapone's competitive position is strongest when adherence and dosing simplicity are clinically important. It is weaker in formularies that place branded adjunctive medicines on unfavorable tiers.
What patents protect Ongentys and when does opicapone lose exclusivity?
Ongentys' U.S. exclusivity consists of regulatory exclusivity and patent protection. The FDA's five-year new chemical entity exclusivity began on the June 26, 2020 approval date and therefore ran through June 26, 2025, subject to statutory adjustments. NCE exclusivity blocks submission of an ANDA referencing the product during the protected period, although a 505(b)(2) application may be subject to different rules. [1][6]
Patent protection can extend beyond regulatory exclusivity. The relevant patent estate may cover the active ingredient, pharmaceutical compositions, dosing regimens, and methods of treating Parkinson's disease motor fluctuations. Orange Book-listed patents are the principal U.S. reference point for ANDA certification and Paragraph IV litigation. The precise expiration dates depend on the patent claims, terminal disclaimers, pediatric extensions, and any patent-term adjustment.
| Exclusivity layer |
Opicapone implication |
| FDA NCE exclusivity |
Prevented ordinary ANDA submission during the five-year period ending in 2025 |
| Composition patents |
Can protect opicapone or its pharmaceutical forms |
| Formulation patents |
May protect capsule composition, stability, or drug delivery characteristics |
| Method-of-use patents |
May cover adjunctive use with levodopa/carbidopa or treatment of motor fluctuations |
| Pediatric exclusivity |
No publicly established six-month extension should be assumed without an FDA-recognized award |
| Orange Book listings |
Determine patent certifications available to ANDA applicants |
The commercial loss-of-exclusivity date should not be treated as identical to the NCE expiration date. A generic applicant may file after NCE exclusivity ends but still face listed patents. Conversely, a Paragraph IV challenge can accelerate litigation before patent expiry.
What is the Orange Book status of Ongentys?
Ongentys is an FDA-approved small-molecule drug and is therefore eligible for Orange Book patent listing. The Orange Book, rather than the product label alone, controls the current list of patents relevant to ANDA applicants. [6]
A patent challenge normally requires one of four certifications:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the listed patent has expired.
- Paragraph III: the applicant will wait until patent expiration.
- Paragraph IV: the listed patent is invalid, unenforceable, or will not be infringed.
A first substantially complete Paragraph IV ANDA may receive 180 days of generic exclusivity if statutory requirements are met. A Paragraph IV notice can trigger a 30-month stay of FDA approval if the patent holder files suit within the statutory period. [7]
Which companies are challenging opicapone patents?
No confirmed U.S. generic approval or commercially launched generic opicapone product is established in the cited regulatory and company materials. Publicly documented ANDA challenges should be evaluated against current FDA Orange Book records and court dockets because filing activity can change after the end of NCE exclusivity.
The most likely challengers are generic companies with neurology portfolios and capsule manufacturing capabilities. The principal barriers are not complex biologic manufacturing or device engineering. They are patent validity, infringement, bioequivalence, supply economics, and the relatively limited size of the market.
What formulation and manufacturing IP protects opicapone?
Opicapone is a chemically synthesized small molecule supplied as an oral capsule. Its manufacturing barriers are therefore lower than those for biologics, long-acting injectables, or implantable delivery systems.
Potentially relevant intellectual property includes:
- Active pharmaceutical ingredient synthesis.
- Crystalline or polymorphic forms.
- Pharmaceutical compositions and excipients.
- Capsule stability and impurity control.
- Dosage regimens with levodopa/carbidopa.
- Treatment methods for end-of-dose wearing-off.
- Process controls needed to achieve consistent bioequivalence.
Manufacturing know-how can delay a generic even when patent protection is weak, but it is unlikely to create a durable barrier comparable to a complex biologic process. Generic companies can usually qualify alternative routes, suppliers, and formulations if the market supports the investment.
What patent litigation and settlement agreements affect Ongentys?
The main U.S. legal risk is a future ANDA Paragraph IV challenge after the end of NCE exclusivity. A litigation settlement could establish an authorized generic, a delayed generic launch date, a license under selected patents, or other commercial terms.
No specific publicly confirmed Ongentys patent settlement should be treated as controlling without a current court filing, FDA record, or company disclosure. The absence of a disclosed settlement leaves the expected generic-entry window dependent on Orange Book patents, litigation timing, and the strength of the relevant claims.
What is the FDA regulatory status of opicapone?
The FDA approved Ongentys through the traditional new drug application pathway in 2020. The label includes warnings and precautions relevant to dopaminergic therapy, including dyskinesia, hypotension or syncope, somnolence, hallucinations or psychotic-like behavior, and impulse-control symptoms. [1]
The regulatory profile is commercially favorable because the product has:
- Full U.S. approval.
- A clear adjunctive indication.
- A simple once-daily regimen.
- No biologic interchangeability issue.
- No biosimilar pathway risk.
Biosimilars are not relevant to opicapone because it is a small-molecule drug. Competition will come through ANDA generics or, potentially, 505(b)(2) products.
What generic-entry risks exist for opicapone?
The most probable generic scenarios are:
| Scenario |
Timing effect |
Commercial effect |
| No early Paragraph IV challenge |
Generic entry follows patent expiry |
Gradual erosion |
| Single first-filer challenge |
Litigation may delay approval |
Potential 180-day limited competition |
| Multiple generic entrants |
Faster price compression |
Sharper branded volume decline |
| Authorized generic launch |
Defends channel share |
Reduces third-party generic economics |
| Weak patent estate |
Earlier entry after NCE expiry |
Significant price and volume pressure |
| Strong method-of-use patents |
May preserve labeled indication |
Does not necessarily block all carve-out competition |
Because generic entacapone is already available, payers and physicians are familiar with low-cost COMT inhibition. That increases the risk of rapid substitution once generic opicapone becomes available, particularly if the generic demonstrates equivalent once-daily dosing and receives broad formulary coverage.
How strong is the opicapone patent estate?
The estate is commercially meaningful but structurally less defensible than the estate surrounding a complex formulation, biologic, or delivery device. Composition-of-matter protection is generally the strongest category. Formulation and method-of-use claims are more vulnerable to validity and design-around arguments.
Patent strength should be assessed across four questions:
- Does a live composition patent cover the exact active ingredient?
- Are listed patents enforceable after terminal disclaimers and patent-term adjustments?
- Can an ANDA applicant avoid infringement through a label carve-out?
- Does the product's commercial value justify Paragraph IV litigation?
Ongentys' moderate market size may reduce the incentive for aggressive litigation if expected post-launch sales do not support substantial legal costs. The same factor can encourage a generic company to enter early if manufacturing costs are low.
What is the revenue exposure for Neurocrine and Bial?
Neurocrine's financial exposure is concentrated in Ingrezza, not Ongentys. Ongentys contributes incremental revenue and supports the company's movement-disorders commercial infrastructure, but it is unlikely to determine corporate valuation unless its growth accelerates sharply or Ingrezza faces a major disruption.
For Bial, opicapone is strategically more important because it originated the product and retains international economics. European pricing, national reimbursement decisions, and country-level generic timing will determine the international revenue trajectory. Europe also presents a fragmented market in which patent expiry and generic substitution vary by country.
Key Takeaways
- Opicapone is a once-daily adjunctive COMT inhibitor for Parkinson's disease "off" episodes.
- Ongentys was approved in the United States on June 26, 2020.
- Neurocrine commercializes Ongentys in the United States under a license from Bial.
- The five-year U.S. NCE exclusivity period ended in June 2025.
- Patent protection may extend beyond NCE exclusivity through composition, formulation, and method-of-use claims.
- The product's strongest commercial advantage is once-daily dosing against entacapone's more frequent administration.
- Generic competition is the principal medium-term risk, not biosimilar substitution.
- Ongentys is financially meaningful as a portfolio product but remains small relative to Neurocrine's Ingrezza franchise.
- The generic launch window depends on current Orange Book listings, Paragraph IV activity, litigation, and any settlement terms.
- The long-term market is likely to be a stable adjunctive Parkinson's product with price pressure after generic entry.
FAQs
Is opicapone a generic drug?
No. Ongentys is the branded reference product. Generic opicapone would generally enter through the FDA's ANDA pathway after applicable regulatory exclusivity and patent barriers expire or are successfully challenged.
Can opicapone be used without levodopa?
The FDA-approved U.S. indication requires use with levodopa/carbidopa. It is not approved as standalone Parkinson's disease therapy.
Does opicapone have biosimilar competition?
No. Opicapone is a small-molecule drug, so competing products would be generics rather than biosimilars.
Why might physicians choose opicapone over entacapone?
The main reason is dosing convenience. Opicapone is taken once daily, while entacapone is generally administered with each levodopa dose. Reimbursement and patient-specific tolerability can outweigh that convenience advantage.
Is Ongentys important to Neurocrine's valuation?
Ongentys provides portfolio diversification and movement-disorders infrastructure, but Neurocrine's valuation and revenue base are primarily driven by Ingrezza. Ongentys would need substantial growth to materially alter the company's consolidated financial profile.
References
-
U.S. Food and Drug Administration. (2020). Ongentys (opicapone) prescribing information. FDA.
-
European Medicines Agency. (2016). Ongentys: EPAR - product information. EMA.
-
Bial. (2017). Bial and Neurocrine Biosciences enter agreement for U.S. development and commercialization of opicapone. Bial.
-
Neurocrine Biosciences, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Neurocrine Biosciences, Inc. (2024). Fourth-quarter and full-year 2023 financial results. Neurocrine Biosciences.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Code, 21 U.S.C. §355(j). (2024). Abbreviated applications for new drugs. Congress.gov.
